Similar to breast cancer, the hyaluronan synthesis inhibitor 4-methylumbelliferone inhibits the formation of bone metastases of prostate cancer partly by blocking the AKT pathway [146]. This evidence concerns the gene AKT1 and prostate carcinoma.